Background and objective: Matrix degradation is a key feature of chronic obstructive pulmonary disease (COPD). Desmosine and isodesmosine (desmosines) are excreted in urine following matrix degradation. The main purpose of this study was to investigate the association between computed tomography (CT) emphysema indices and urinary desmosines in patients with COPD. Methods: A total of 152 subjects were selected from the Korean Obstructive Lung Disease cohort. Their urine samples were assayed for desmosines using liquid chromatography-tandem mass spectrometry (LC-MS/ MS) methods. The cohort was divided into emphysemadominant (n = 80) and non-emphysema dominant-(n = 72) groups according to the CT emphysema index. Results: The level of urinary desmosines was significantly higher in the emphysema-dominant group. Significant differences were also observed between the two groups for body mass index and lung function. Multivariate analysis indicated that a high level of urinary desmosines was a significant independent predictor of emphysema (relative risk: 2.6; 95% CI: 1.11-6.09; P = 0.028). The percentage of frequent exacerbators was significantly higher in the high urinary desmosine group in the first year of follow-up (P = 0.041). The mean number of exacerbations was higher in the high urinary desmosine group, although this difference was not statistically significant (P = 0.067). The changes in
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is persistent 
SUMMARY AT A GLANCE
Previous studies have revealed inconsistencies as to the association between emphysema severity and desmosines released due to matrix degradation in chronic obstructive pulmonary disease (COPD). This study suggests that urinary desmosines, measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods, are useful for predicting emphysema severity and frequent exacerbation in patients with COPD. and usually progressive. 1 COPD is a leading cause of morbidity and mortality worldwide, with economic and social burdens that are substantial and increasing. 1 Accordingly, there is growing interest in research that evaluates the effectiveness and reliability of potential COPD biomarkers. Nevertheless, there is currently no universal biomarker indicative of the pathogenic processes, disease progression or pharmacological responses, mainly due to the many different factors that contribute to the disease. 2 Elastin is the principal component of elastic fibres. Normal structure and function of the lung parenchyma largely depend upon elastic fibres.
3 Matrix degradation is a major feature of COPD, and disruption of elastic fibres in the alveolar wall is a key characteristic of pulmonary emphysema. 4 Elastic fibres are formed by tropoelastin monomers cross-linked by desmosine and isodesmosine (desmosines), which are unique to mature elastin. 4 Desmosines are released as a result of elastic fibre degradation, and can be found in sputum, blood and urine. 5 Albarbarawi et al. and Ma et al. demonstrated that liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a sensitive, accurate and reproducible method, 6, 7 and proposed it as the gold standard method to measure desmosines. 7 Most studies have analysed urinary desmosines rather than plasma desmosines, probably due to the higher concentrations in the urine. One study showed that lung function measures in subjects with COPD were more significantly correlated with levels of urinary desmosines than plasma desmosines. 8 Another study observed that, while levels of urinary desmosines were increased by exacerbations, they were unable to discriminate between healthy smokers and patients with stable COPD; conversely, levels of plasma desmosines were higher in patients with stable COPD than in healthy smokers, but were unable to differentiate between stable COPD and exacerbations. 9 The computed tomography (CT) emphysema index is another surrogate end-point of lung destruction in COPD. 10 In the 1990s, two studies evaluated the relationship between plasma elastin-derived peptides and CT emphysema scores, but obtained conflicting results. 11, 12 Subsequently, only one small study revealed a significant correlation between CT emphysema extent and urinary desmosine excretion, analysed by the enzyme-linked immunoabsorbent assay (ELISA) method. 13 Therefore, the main purpose of the present study was to investigate the association between the CT emphysema severity index and urinary desmosines using LC-MS/MS methods in patients with COPD. We also examined the relationship between baseline levels of urinary desmosines and subsequent exacerbation of COPD.
METHODS

Study participants
The Korean Obstructive Lung Disease (KOLD) cohort comprises patients with COPD or asthma recruited from the pulmonary clinics of 11 referring hospitals in South Korea between June 2005 and April 2011. The inclusion criteria for the present study were: (i) a smoking history ≥10 pack-years, (ii) a ratio of postbronchodilator forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity (FVC) < 0.7 and (iii) the availability of volumetric CT data. Among 344 patients with COPD in the KOLD cohort, 180 patients were randomly selected and their baseline levels of urinary desmosines were acquired for measurement. However, 28 of them were excluded because their urine samples were lost during the process of overnight hydrolysis. Thus, a total of 152 subjects from the KOLD cohort had baseline urinary desmosines that could be analysed.
The study was approved by the institutional review boards of all 11 participating hospitals. Written informed consent was obtained from all patients (see Appendix S1, Supplementary Information, for site names and protocol numbers).
Quantitative measurements of urinary desmosines
For each patient, ≥5 mL of random spot urine was collected at enrolment, and was anonymized, frozen and stored at −80 C. Urine samples were assayed for desmosines using LC-MS/MS methods (Thermo Scientific, San Jose, CA, USA). The levels of urinary desmosines were expressed as a total desmosine concentration normalized to urinary creatinine concentration according to previous reports 6, 10 (see Appendix S2, Supplementary Information, for details on sample preparation and LC-MS/MS methods).
CT measurements
Prior to inclusion in the study, all patients underwent volumetric CT scans during full inspiration and expiration using a 16-multidetector CT scanner (Somatom Sensation, Siemens, Erlangen, Germany; GE Lightspeed Ultra Instrument, General Electric Healthcare; Milwaukee, WI, USA; Philips Brilliance Instrument, Philips Medical Systems, Best, the Netherlands). Images of the whole lung were extracted automatically and the attenuation coefficient of each pixel was calculated. The cut-off level between normal lung density and low-attenuation areas was defined as −950 Hounsfield units (HU).
14 The volume fraction of the lung below −950 HU was calculated automatically at full inspiration, and termed the emphysema index.
St George's Respiratory Questionnaire
The validated Korean version of the St George's Respiratory Questionnaire (SGRQ) was used to assess healthrelated quality of life. 15 The SGRQ covers three domains: symptoms (relating to cough, sputum, wheeze and shortness of breath); activity (relating to physical activities that cause or are limited by breathlessness); and impact (relating to control, panic, medication and expectations).
Exacerbation
Exacerbation was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria as a worsening of the patient's respiratory symptoms (dyspnoea, cough or sputum) for a period of two or more days that required additional treatment with systemic steroids or antibiotics, a visit to the emergency room and/or hospital admission. In addition, patients who experienced exacerbations twice or more for the first year of follow-up were categorized as frequent exacerbators.
Statistical analysis
All statistical analyses were performed using the statistical software package PASW Statistics v18.0.0 (IBM Co., Armonk, NY, USA). Bivariate comparisons were made using Student's t-test, Mann-Whitney U-test, Pearson's chi-square test or Fisher's exact test. Oneway analysis of variance (ANOVA) was used to make between-group comparisons of the mean levels of urinary desmosines according to airflow limitations (three groups). Logistic regression analysis was used to identify independent factors associated with emphysema severity. To assess changes in CT emphysema severity indices over time, repeated measures ANOVA was performed. The last observation carried forward method was used to account for missing data. A value of P ≤ 0.05 was considered statistically significant.
RESULTS
Baseline characteristics
Baseline demographic and disease characteristics of the 152 patients who took part in the study were as follows: mean age, 66.3 years; six females (3.9%); mean body mass index (BMI), 23.2 kg/m 2 ; average smoking, 47.6 pack-years; mean pre-and post-bronchodilator FEV 1 , 1.40 and 1.56 L (46.5% and 51.8% of predicted), respectively; COPD severity (as per previous GOLD guidelines), 2.0% mild, 51.3% moderate, 40.8% severe and 5.9% very severe.
Mean levels of urinary desmosines differed according to the severity of airflow limitation (P < 0.001), and increased with severity of airflow obstruction. High urinary desmosine was defined as a level ≥12 ng/mg creatinine, which was close to the mean desmosine level of the severe COPD patients (Fig. 1) .
Differences between study groups
We classified the subjects into two groups based on their CT emphysema severity index; we labelled those ≥20% the emphysema-dominant group and those <20% the non-emphysema-dominant group. The cut-off value for the emphysema index was determined arbitrarily, similar to the median value (21.3%). The baseline data of the emphysema-dominant group (n = 80) and the non-emphysema-dominant group (n = 72) were then compared.
The baseline level of urinary desmosines was significantly higher in the emphysema-dominant group. Several other characteristics, such as BMI, lung function, 6-min walk distance and SGRQ score, were also significantly different between the two groups. However, no between-group differences were observed for age, smoking history or co-morbidity index (Table 1 ). There were no significant differences between the level of urinary desmosines of current smokers and ex-smokers (11.1 AE 13.0 ng/mg creatinine vs 10.7 AE 11.7 ng/mg creatinine, P = 0.872).
Factors associated with emphysema severity
A positive linear correlation was observed between the level of urinary desmosines and the emphysema index (r = 0.30, P < 0.001). Multiple regression analysis also revealed that the emphysema index was significantly related to BMI (β = −1.21, P = 0.005), FEV 1 (β = −0.20, P = 0.019) and the level of urinary desmosines (β = 0.21, P = 0.042). Multivariate logistic regression revealed that level of urinary desmosines and BMI were independently associated with the emphysema-dominant group, whilst high urinary desmosines was independently associated with emphysema, with a relative risk of 2.6 (95% CI: 1.11-6.09; P = 0.028) ( Table 2 ). However, no significant associations were found with FEV 1 .
Exacerbations for the first year of follow-up
There was no significant difference in exacerbation rates between high and low urinary desmosine groups (P = 0.221). However, the percentage of frequent exacerbators was significantly higher in the high urinary desmosine group for the first year of follow-up (P = 0.041). The mean number of exacerbations was higher in the high urinary desmosine group, although this difference was not statistically significant (P = 0.067) ( Table 3) .
Changes in CT emphysema indices over 3 years
The emphysema indices of patients with high urinary desmosine tended to increase slightly over 3 years (approximately 0.5% per year). However, repeated measures ANOVA did not reveal any significant difference in the changes of CT emphysema indices between the high and low urinary desmosine groups (P = 0.412) (Fig. 2) . Seven patients were excluded from this analysis (reasons: six deaths and one early drop-out before 3-year follow-up). Figure 1 The means and SE of urinary desmosines according to the severity of airflow limitation (n = 152). Only three patients showed mild airflow limitation, and were included in the mild and moderate group.
DISCUSSION
The present study aimed to investigate the association between the CT emphysema severity index and urinary desmosine levels in patients with COPD from the KOLD cohort. It demonstrated that the level of urinary desmosines was independently associated with emphysema severity, and that COPD patients with high urinary desmosine levels have an increased risk (approximately 2.6-fold) of emphysema dominance. This study also showed that frequent exacerbators were more common in the high urinary desmosine group.
The positive association between the emphysema index and level of urinary desmosines in COPD patients seems intuitive, given the potentially causal relationship in the pathogenic process of emphysema. A few previous small studies obtained conflicting results, in which elastin-derived peptides were measured by different ELISA methods. [11] [12] [13] Importantly, the present study measured urinary desmosines using LC-MS/MS methods, which is considered the gold standard for detection. 16 Recent data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, obtained using LC-MS/MS Plus-minus values are means AE SD. BMI is the weight in kg divided by the square of height in metres. † Scores on the SGRQ range from 0 to 100, with lower scores indicating improvement; a change of 4 units or more is considered clinically meaningful.
‡ The volume fraction of the lung below −950 HU was calculated automatically at full inspiration, and termed the emphysema index. The air-trapping index was estimated by calculating the ratio of mean lung density at expiration and inspiration. The airway index was defined as the ratio of wall area per wall area plus lumen area.
CT, computed tomography; Desmosines, desmosine and isodesmosine; DL CO , carbon monoxide diffusion capacity; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; High urinary desmosines, a level of urinary desmosines ≥12 ng/mg creatinine; HU, Hounsfield units; MMRC, Modified Medical Research Council; SGRQ, St George's Respiratory Questionnaire. method, did not assess the relationship between urinary desmosines and the parameters linked with elastin degradation such as emphysema severity or diffusion capacity. 17 Therefore, the present study shows for the first time that the level of urinary desmosines measured by LC-MS/MS methods is associated with the CT emphysema index.
The present study indicates that BMI is independently associated with emphysema severity in patients with COPD. This finding is supported by several previous reports concerning the inverse association between BMI and CT emphysema severity in COPD patients. 18, 19 The present study also revealed that the proportion of frequent exacerbators was higher in patients with high urinary desmosines in the first year of follow-up. Previous research suggests that urinary excretion of desmosines is significantly increased during acute exacerbations of COPD. 9, 20, 21 However, the relationship between baseline urinary desmosines and subsequent COPD exacerbations had not previously been explored. The present study suggests, for the first time, that baseline levels of urinary desmosines are related to frequent exacerbation in patients with COPD. This is consistent with the previous KOLD cohort study, which showed that the severity of emphysema (a higher CT emphysema index) was an independent predictor of frequent exacerbation in COPD patients, 22 as desmosines are released due to matrix degradation that eventually leads to pulmonary emphysema.
Additionally, our results showed that the level of urinary desmosines increased as airflow limitation became more severe. This result corresponds with recent reports that have evaluated discrete levels of urinary desmosines in relation to the severity of airflow limitation. 8, 23 However, there were some discrepancies in the levels of urinary desmosines recorded within these studies and, as a result, there is currently a lack of consensus as to the high level of urinary desmosines in patients with COPD. In the present study, we determined the cut-off value for the high level of urinary desmosines arbitrarily, as very close to the mean level of severe COPD patients. We also classified the subjects into two groups based on a CT emphysema severity index cut-off value of 20% (participants with an emphysema index ≥20% was considered emphysema dominant) that was based on a previous KOLD study that explored treatment response according to COPD subtypes. 24 In the present study, we attempted to evaluate the difference between the longitudinal changes in CT emphysema indices in the high and low urinary desmosine groups. No significant difference was observed over 3 years. In the latest report on COPD and desmosines, although measured in plasma, no significant correlation was found between the level of desmosines and progression of emphysema for 3 years. 25 We believe that 3 years may be a too short period to differentiate between group changes in emphysema severity indices, because the rate of emphysema progression is slow (approximately only 1% per year in a follow-up study of male smokers). 26 Therefore, a longer follow-up period is required to evaluate longitudinal changes of emphysema severity in subgroups of COPD patients.
This study had several limitations. First, the number of study subjects was relatively small. Second, no significant differences were observed in the levels of urinary desmosines in current smokers and ex-smokers. However, a previous study reported that current smoking was associated with increased levels of urinary desmosines. 8 Therefore, our finding is unexpected, and future work should consider nicotine or cotinine tests at enrolment to ascertain actual smoking status, and a comprehensive history should be taken including second-hand smoke and biomass fuel exposure to further evaluate this association. Third, only a small number of female patients were included in the present study. Therefore, the results cannot be generalized to female patients with COPD, given that previous work has highlighted the influence of gender in COPD manifestation. 27 In conclusion, urinary desmosines measured by LC-MS/MS methods may be an effective clinical parameter for predicting emphysema severity in patients with COPD. Our subgroup of patients with high levels of High desmosine group urinary desmosines had an increased risk of emphysema dominance. Moreover, frequent exacerbation of COPD may be associated with high baseline levels of urinary desmosines. Nevertheless, further studies among larger cohorts of patients are warranted to clarify the results. Long-term follow-up studies of changes in CT emphysema indices should also be considered to determine emphysema progression among subgroups of patients with different baseline levels of urinary desmosines.
